Crónica de una compra anunciada: Al fin se dió, Lilly formaliza la compra de ImClone

L
Se concretó, al fin, por 6.5 billion $.

“By bringing together ImClone’s and Lilly’s marketed oncology products, pipelines and biotech capabilities, we are taking a very important step forward in addressing the challenges of patent expirations we will face early in the next decade,” según declaró John C. Lechleiter, Lilly’s CEO

Mas...